SEC Form 4 · accession 0000925421-17-000365
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dino A Rossi
Director
Period of report
Sep 22, 2017
Accepted (ET)
Sep 25, 2017 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 22, 2017 | C | 123,691 | — | A | 123,691 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred StockF1 | — | Sep 22, 2017 | C | 123,691 | D | — | — | Common Stock | 123,691 | 0 | D |
| Stock Option (Right to Buy) | $8.79 | holding | — | — | — | Jun 1, 2021 | Jun 1, 2027 | Common Stock | 18,949 | 18,949 | D |
Explanation of responses
- F1The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.